R1	Has_value Arg1:T3 Arg2:T2	
R2	Has_multiplier Arg1:T8 Arg2:T9	
R3	Has_multiplier Arg1:T10 Arg2:T9	
R4	multi Arg1:T14 Arg2:T13	
R5	Has_qualifier Arg1:T12 Arg2:T14	
R6	Has_value Arg1:T16 Arg2:T17	
R7	multi Arg1:T15 Arg2:T16	
R8	Has_temporal Arg1:T18 Arg2:T19	
R9	AND Arg1:T15 Arg2:T18	
R10	Has_negation Arg1:T22 Arg2:T23	
R11	multi Arg1:T27 Arg2:T26	
R12	Has_value Arg1:T26 Arg2:T25	
R13	Subsumes Arg1:T25 Arg2:T28	
R14	AND Arg1:T22 Arg2:T27	
R15	Has_temporal Arg1:T32 Arg2:T34	
*	OR T32 T31 T33
R16	Has_qualifier Arg1:T36 Arg2:T39	
R17	Has_qualifier Arg1:T37 Arg2:T39	
R18	Has_context Arg1:T32 Arg2:T36	
R19	Has_mood Arg1:T42 Arg2:T43	
R20	Has_temporal Arg1:T42 Arg2:T44	
R21	multi Arg1:T49 Arg2:T51	
R22	multi Arg1:T48 Arg2:T50	
*	OR T46 T47
R23	Has_mood Arg1:T46 Arg2:T45	
R24	Has_temporal Arg1:T46 Arg2:T48	
R25	Has_temporal Arg1:T46 Arg2:T49	
R26	Has_negation Arg1:T46 Arg2:T56	
R27	Has_mood Arg1:T53 Arg2:T57	
R28	Has_temporal Arg1:T53 Arg2:T55	
R29	Has_index Arg1:T19 Arg2:T20	
R30	Subsumes Arg1:T25 Arg2:T29	
R31	Has_mood Arg1:T54 Arg2:T57	
R32	Has_temporal Arg1:T54 Arg2:T55	
T1	Person 3 8	Women
T2	Value 9 23	18 to 40 years
T3	Person 27 30	age
T4	Observation 45 78	can give written informed consent
T5	Post-eligibility 45 78	can give written informed consent
T6	Post-eligibility 83 168	Available for all visits and consent to follow all procedures scheduled for the study
T7	Post-eligibility 173 267	Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method
T8	Drug 203 206	gel
T9	Multiplier 182 187	daily
T10	Procedure 211 221	monitoring
T11	Condition 272 279	Healthy
T12	Condition 298 313	sexually active
T13	Observation 284 297	self-reported
T14	Qualifier 284 297	self-reported
T15	Condition 318 330	HIV-negative
T16	Measurement 318 321	HIV
T17	Value 322 330	negative
T18	Measurement 350 364	HIV rapid test
T19	Temporal 365 386	at time of enrollment
T20	Reference_point 368 386	time of enrollment
T21	Pregnancy_considerations 391 568	On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment
T22	Drug 602 619	exogenous hormone
T23	Negation 580 587	absence
T25	Value 645 652	regular
T26	Measurement 653 668	menstrual cycle
T27	Condition 645 668	regular menstrual cycle
T28	Value 689 707	minimum of 21 days
T29	Value 714 732	maximum of 36 days
T31	Procedure 764 784	speculum examination
T32	Procedure 757 763;773 784	pelvic examination
T33	Procedure 789 799	colposcopy
T34	Temporal 800 825	at the time of enrollment
T36	Observation 842 848	vagina
T37	Observation 831 837	cervix
T38	Value 856 862	normal
T39	Qualifier 856 862	normal
T40	Subjective_judgement 863 896	as determined by the investigator
T42	Condition 918 936	genital infections
T43	Mood 901 913	Asymptomatic
T44	Temporal 937 962	at the time of enrollment
T45	Mood 968 975	Willing
T46	Drug 999 1015	vaginal products
T47	Drug 1019 1026;999 1006	objects vaginal
T48	Temporal 1027 1061	within 14 days prior to enrollment
T49	Temporal 1066 1095	for the duration of the study
T50	Reference_point 1051 1061	enrollment
T51	Reference_point 1086 1095	the study
T53	Observation 1137 1161	adherence questionnaires
T54	Observation 1119 1132;1147 1161	acceptability questionnaires
T55	Temporal 1162 1182	throughout the study
T56	Negation 979 986	refrain
T57	Mood 1101 1108	Willing
T59	Post-eligibility 1188 1284	Willing to refrain from participation in any other research study for the duration of this study
T60	Post-eligibility 1101 1182	Willing to answer acceptability and adherence questionnaires throughout the study
T61	Post-eligibility 1290 1413	Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures
T62	Non-query-able 1290 1413	Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures
T63	Non-query-able 1188 1284	Willing to refrain from participation in any other research study for the duration of this study
T64	Non-query-able 1101 1182	Willing to answer acceptability and adherence questionnaires throughout the study
